At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to find the best dose of BMS-986504 to use safely in people with lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their tumors are missing the MTAP gene.
- A Study Using Immune Suppression Prior to Stem Cell Transplant for Children and Adults with Sickle Cell Disease or Beta-Thalassemia
Full Title Pre-Transplant Immune Suppression with Hematopoietic Cell Transplantation from Haploidentical Donors for Adults and Children with Sickle Cell Disease or ß-Thalassemia (Haplo PTCy)
Purpose
Sickle cell disease and beta-thalassemia are blood diseases caused by a genetic change (mutation) in hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with these diseases may be offered a stem cell transplant. Stem cell transplantation involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in the bone marrow.
In this study, researchers want to determine if giving medications to quiet down the immune system before standard conditioning therapy and stem cell transplantation can reduce the risk of serious side effects of transplant. Participants will receive fludarabine and dexamethasone (medications that lower the activity of the immune system) before standard conditioning therapy and stem cell transplantation. Depending on how the body responds to fludarabine and dexamethasone, the study doctor may decide a patient should receive another medication, called cyclophosphamide, instead of fludarabine. In addition, depending on the results of routine blood tests, participants may receive the drugs bortezomib and rituximab, which also help with immune suppression.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have sickle cell disease or beta-thalassemia and be candidates for a donated stem cell transplant.
- Prior stem cell transplantation from a donor is not permitted.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people ages 2-50.
Contact
For more information about this study and to ask about eligibility, please contact 1-833-MSK-KIDS.
Protocol
23-009Phase
Phase II (phase 2)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05736419ClinicalTrials.gov
-
TLN-372 may help slow or stop the growth of your cancer by blocking the KRAS protein. 
-
Padeliporfin VTP (vascular targeted photodynamic) therapy uses targeted laser light to destroy cancer cells while causing minimal damage to the tissues around the cancer. In this study, researchers want to learn if padeliporfin VTP therapy is effective and safe for people with low-grade upper urothelial cancers (tumors of the kidney or ureter) that have not spread.
-
Researchers want to find the best dose of EVM14 when used alone or with pembrolizumab in people with solid tumors. The people in this study have a solid tumor that keeps growing after treatment and has spread. This study includes people with:
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Aromatase inhibitors (AIs) are drugs that many people take for several years after initial breast cancer treatment. They are designed to reduce the chance that the breast cancer will come back. However, people who take AIs often develop a type of joint pain known as aromatase inhibitor-associated arthralgia (AIA). Those with AIA often reduce their physical activity and have an increased risk of falling. Some people stop taking their AIs because of this pain.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to find the best dose of BMS-986458 to use alone and with rituximab to treat lymphoma. The people in this study have non-Hodgkin lymphoma (NHL) that came back or keeps growing after treatment.
- A Phase 2 Study Assessing Treatment for Inflammation Before a Stem Cell Transplant in People with Immune and Autoinflammatory Conditions
Full Title Phase 2 Study Bridging Pre-Transplant Inflammatory Dampening for Primary Immune Regulatory Disorders (BRIDGE Trial)
Purpose
Primary immune regulatory disorder (PIRD) and autoinflammatory conditions are conditions of the immune system that can cause an unusual amount of inflammation. While a stem cell transplant is a standard treatment for people with a PIRD or autoinflammatory condition, the inflammation caused by these conditions can reduce the effectiveness of this treatment.
In this study, researchers are assessing treatment before transplant with emapalumab or fludarabine/dexamethasone in people with a PIRD and/or an autoinflammatory condition who are planning to have a stem cell transplant. Emapalumab or fludarabine/dexamethasone are drugs that may help reduce inflammation and enable people with a PIRD and/or an autoinflammatory condition to have a successful stem cell transplant. These drugs work by either directly blocking proteins that cause inflammation or inactivating immune cells that promote inflammation.
The medications used in this study are given intravenously (by vein). Participants will receive one of two study treatments before their stem cell transplant:
- Emapalumab
- Fludarabine and dexamethasone
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have a PIRD and/or an autoinflammatory condition and be planning to have a stem cell transplant.
- Patients must have an appropriate stem cell donor.
- This study is for people of all ages.
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Joseph Oved at 646-888-3314.
Protocol
23-040Phase
Phase II (phase 2)Disease Status
Newly DiagnosedInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05787574ClinicalTrials.gov